Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma. - Wobser M; Rosenwald A; Eisele F; Maurus K; Topp M; Duell J (Leukemia & lymphoma, 2026)